EU trims exclusivity window for new drugs
NegativeFinancial Markets

- The European Union has decided to shorten the exclusivity period for new drugs, allowing cheaper generics to enter the market a year earlier than previously allowed. This move aims to reduce healthcare costs and increase access to medications for patients across the EU.
- This decision is significant as it reflects the EU's commitment to making healthcare more affordable, potentially impacting pharmaceutical companies' revenue streams and their investment in research and development for new drugs.
- The change in drug exclusivity aligns with broader EU initiatives to enhance competitiveness and reduce dependency on external markets, as seen in recent plans to cut reliance on Chinese raw materials and address investment barriers within the bloc.
— via World Pulse Now AI Editorial System






